Skip to main content
NCBI home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 1991;3(2):167–175. doi: 10.1007/BF02172089

Evaluation of TNF as antiviral, antibacterial and antiparasitic agent

Graham A W Rook 1,✉, Janice Taverne 2, John H L Playfair 2
PMCID: PMC7102365  PMID: 2054257

The content is available as a PDF (979.9 KB).

References

  • 1.Havell EA. Production of tumor necrosis factor during murine listeriosis. J Immunol. 1987;139:4225–31. [PubMed] [Google Scholar]
  • 2.Nakane A, Minagawa T, Kato K. Endogeneous tumour necrosis factor (cachectin) is essential to host resistance against Listeria monocytogenes infection. Infect Immun. 1988;56:2563–9. doi: 10.1128/iai.56.10.2563-2569.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Bancroft GJ, Sheehan KC, Schreiber RD, Unanue ER. Tumor necrosis factor is involved in the T cell-independent pathway of macrophage activation in scid mice. J Immunol. 1989;143:127–30. [PubMed] [Google Scholar]
  • 4.Kindler V, Sappino AP, Grau GE, Piguet PF, Vassalli P. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell. 1989;56:731–40. doi: 10.1016/0092-8674(89)90676-4. [DOI] [PubMed] [Google Scholar]
  • 5.Neifer S, Kremsner PG, Bienzle U. Application of anti-TNF to plasmodium vinckei-infected mice is followed by an increase of parasitaemia. Acta Trop (Basel) 1989;46:273–5. doi: 10.1016/0001-706x(89)90029-6. [DOI] [PubMed] [Google Scholar]
  • 6.Titus RG, Sherry B, Cerami A. Tumour necrosis factor plays a protective role in experimental murine cutaneous leismaniasis. J exp Med. 1989;170:2097–104. doi: 10.1084/jem.170.6.2097. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Taverne J, Tavernier J, Fiers W, Playfair JH. Recombinant tumour necrosis factor inhibits malaria parasitein vivo but notin vitro. Clin Exp Immunol. 1987;67:1–4. [PMC free article] [PubMed] [Google Scholar]
  • 8.Clark IA, Hunt NH, Butcher GA, Cowden WB. Inhibition of murine malaria (plasmodium chabaudi)in vivo by recombinant interferon-gamma or tumor necrosis factor, and its enhancement by butylated hydroxyanisole. J Immunol. 1987;139:3493–6. [PubMed] [Google Scholar]
  • 9.Black CM, Israelski DM, Suzuki Y, Remington JS. Effect of recombinant tumour necrosis factor on acute infection in mice with toxoplasma gondii or Trypanosoma cruzi. Immunology. 1989;68:570–4. [PMC free article] [PubMed] [Google Scholar]
  • 10.Bermudez LEM, Stevens P, Kolonoski P, Wu M, Young LS. Treatment of experimental disseminated Mycobacterium avium complex infection in mice with recombinant IL-2 and tumor necrosis factor. J Immunol. 1989;143:2996–3000. [PubMed] [Google Scholar]
  • 11.Blanchard DK, Djeu JY, Klein TW, Friedman H, Stewart WE. Protective effects of tumor necrosis factor in experimental Legionella pneumophila infections of mice via activation of PMN function. J Leukoc Biol. 1988;43:429–35. doi: 10.1002/jlb.43.5.429. [DOI] [PubMed] [Google Scholar]
  • 12.Parant M. Effects of TNF in bacterial infections. Ann Inst Pasteur Immunol. 1988;139:301–4. doi: 10.1016/0769-2625(88)90145-6. [DOI] [PubMed] [Google Scholar]
  • 13.Cross AS, Sadoff JC, Kelly N, Bernton E, Gemski P. Pretreatment with recombinant murine tumour necrosis factor alpha/cachectin and murine interleukin 1 alpha protects mice from lethal bacterial infection. J Exp Med. 1989;169:2021–7. doi: 10.1084/jem.169.6.2021. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, Lowry SF, Cerami A. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature. 1987;330:662–4. doi: 10.1038/330662a0. [DOI] [PubMed] [Google Scholar]
  • 15.Doherty PC, Allan JE, Clark IA. Tumour necrosis factor inhibits the development of viral meningitis or induces rapid death depending on the severity of inflammation at the time of administration. J Immunol. 1989;142:3576–80. [PubMed] [Google Scholar]
  • 16.Kongshavn PA, Ghadirian E. Effect of tumour necrosis factor on growth of Trypanosoma musculiin vivo andin vitro. Adv Exp Biol Med. 1988;239:257–62. doi: 10.1007/978-1-4757-5421-6_26. [DOI] [PubMed] [Google Scholar]
  • 17.Usami H, Yamamoto A, Yamashita W, Sugawara Y, Hamada S, Yamamoto T, Kato K, Kokeguchi S, Ohokuni H, Kotani S. Antitumour effects of streptococcal lipoteichoic acids on Meth A fibrosarcoma. Br J Cancer. 1988;57:70–3. doi: 10.1038/bjc.1988.11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Moreno C, Taverne J, Mehlert A, Bate CA, Brealey RJ, Meager A, Rook GAW, Playfair JHL. Lipoarabinomannan from mycobacterium tuberculosis induces the production of tumour necrosis factor from human and murine macrophages. Clin Exp Immunol. 1989;76:240–5. [PMC free article] [PubMed] [Google Scholar]
  • 19.Jupin C, Anderson S, Damais C, Alouf JE, Parant M. Toxic shock syndrome toxin 1 as an inducer of human tumor necrosis factors and gamma interferon. J Exp Med. 1988;167:752–61. doi: 10.1084/jem.167.3.752. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Yamamoto A, Nagamuta M, Usami H, Sugawara Y, Watanabe N, Niitsu Y, Urushizaki I. Release of tumour necrosis factor (TNF) into mouse peritoneal fluids by OK432, a streptococcal preparation. Immunopharmacology. 1986;11:79–86. doi: 10.1016/0162-3109(86)90027-5. [DOI] [PubMed] [Google Scholar]
  • 21.Noso Y, Parant M, Parant F, Chedid L. Production of tumour necrosis factor in nude mice by muramyl peptides associated with bacterial vaccines. Cancer Res. 1988;48:5766–9. [PubMed] [Google Scholar]
  • 22.Bate CA, Taverne J, Playfair JH. Soluble malarial antigens are toxic and induce the production of tumour necrosis factorin vivo. Immunology. 1989;66:600–5. [PMC free article] [PubMed] [Google Scholar]
  • 23.Djeu JY, Blanchard DK, Richards AL, Friedman H. Tumor necrosis factor induction by candida albicans from human natural killer cells and monocytes. J Immunol. 1988;141:4047–52. [PubMed] [Google Scholar]
  • 24.Playfair JHL, Taverne J, Bate CAW, De Souza JB. The malaria vaccine: anti-parasite or anti-disease? Immunology Today. 1990;11:25–7. doi: 10.1016/0167-5699(90)90007-v. [DOI] [PubMed] [Google Scholar]
  • 25.Roux-Lombard P, Modoux C, Cruchaud A, Dayer JM. Purified blood monocytes from HIV 1-infected patients produce high levels of TNF alpha and IL-1. Clin Immunol Immunopathol 50: 374-84. [DOI] [PubMed]
  • 26.Molina JM, Scadden DT, Byrn R, Dinarello CA, Groopman JE. Production of tumor necrosis factor alpha and interleukin 1 beta by monocytic cells infected with human immunodeficiency virus. J Clin Invest. 1989;84:733–7. doi: 10.1172/JCI114230. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Merrill JE, Koyanagi Y, Chen IS. Interleukin-1 and tumor necrosis factor alpha can be induced from mononuclear phagocytes by human immunodeficiency virus type 1 binding to the CD4 receptor. J Virol. 1989;63:4404–8. doi: 10.1128/jvi.63.10.4404-4408.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Klebanoff SJ, Vadas MA, Harlan JM, Sparks LH, Gamble JR, Agosti JM, Waltersdorf AM. Stimulation of neurophils by tumour necrosis factor. J Immunol. 1986;136:4220–5. [PubMed] [Google Scholar]
  • 29.Berkow RL, Dodson MR. Biochemical mechanisms in the priming of neutrophils by tumour necrosis factor. J Leukocyte Biol. 1988;44:345–52. doi: 10.1002/jlb.44.5.345. [DOI] [PubMed] [Google Scholar]
  • 30.Ferrante A. Tumor necrosis factor alpha potentiates neutrophil antimicrobial and Candida albicans and associated increases in oxygen radical production and lysosomal enzyme release. Infect Immun. 1989;57:2115–22. doi: 10.1128/iai.57.7.2115-2122.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Gamble JR, Harlan JM, Klebanoff SJ, Vadas MA. Stimulation of the adherence of neutrophils to the umbilical vein endothelium by human recombinant tumour necrosis factor. Proc Natl Acad Sci USA. 1985;82:8667–71. doi: 10.1073/pnas.82.24.8667. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Shalaby MR, Aggarwal BB, Rinderknecht E, Svedersky LP, Finkle BS, Palladino MA. Activation of human polymorphonuclear functions by interferon gamma and tumor necrosis factors. J Immunol. 1985;135:2069–73. [PubMed] [Google Scholar]
  • 33.Shalaby MR, Palladino MA, Hirabayashi SE, Eesalu TE, Lewis GD, Shepard HM, Aggarwal BB. Receptor binding and activation of polymorphonuclear neutrophils by tumour necrosis factor alpha. J Leukocyte Biol. 1987;41:196–204. doi: 10.1002/jlb.41.3.196. [DOI] [PubMed] [Google Scholar]
  • 34.Djeu JY, Blanchard DK, Halkias D, Friedman H. Growth inhibition of candida albicans by human polymorphonuclear neutrophils: activation by interferon gamma and tumor necrosis factor. J Immunol. 1986;137:2980–4. [PubMed] [Google Scholar]
  • 35.Damonneville M, Wietzerbin J, Pancre V, Joseph M, Delanoye A, Capron A, Auriault C. Recombinant tumour necrosis factors mediate platelet cytotoxicity to schistosoma mansoni larvae. J Immunol. 1988;140:3962–5. [PubMed] [Google Scholar]
  • 36.DeTitto EH, Catterall JR, Remington JS. Activity of recombinant tumour necrosis factor on toxoplasma gondii and trypanosoma cruzi. J Immunol. 1986;137:1342–5. [PubMed] [Google Scholar]
  • 37.Wirth JJ, Kierszenbaum F. Recombinant tumour necrosis factor enhances macrophage destruction of trypanosoma cruzi in the presence of bacterial endotoxin. J Immunol. 1988;141:286–8. [PubMed] [Google Scholar]
  • 38.Bermudez LE, Young LS. Tumour necrosis factor, alone or in combination with IL-2, but not IFN-gamma, is associated with macrophage killing of mycobacterium avium complex. J Immunol. 1988;140:3006–13. [PubMed] [Google Scholar]
  • 39.Rook GAW, Steele J, Ainsworth M, Champion BR. Activation of macrophages to inhibit proliferation of mycobacterium tuberculosis: comparison of the effects of recombinant gamma-interferon on human monocytes and murine peritoneal macrophages. Immunology. 1986;59:333–8. [PMC free article] [PubMed] [Google Scholar]
  • 40.Voth R, Rossol S, Gallati H, Pracht I, Laubenstein HP, Hess G, Muller WE, Schroder HC, Jochum C, Meyer-zum-Buschenfelde KH. In vivo andin vitro induction of natural killer cells by cloned human tumour necrosis factor. Cancer Immunol Immunother. 1988;27:128–32. doi: 10.1007/BF00200016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Silberstein DS, David JR. Tumour necrosis factor enhances eosinophil toxicity of schistosoma mansoni larvae. Proc Natl Acad Sci USA. 1986;83:1055–9. doi: 10.1073/pnas.83.4.1055. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Whitcombe EA, Wesolek JH, Pincus SH. Modulation of human peripheral blood eosinophil function by tumour necrosis factor alpha. Int Arch Allergy Appl Immunol. 1989;89:250–5. doi: 10.1159/000234955. [DOI] [PubMed] [Google Scholar]
  • 43.Alam R, Welter JB, Forsythe PA, Lett-Brown MA, Grant JA. Comparative effect of recombinant IL-1, -2, -3, -4, and -6, IFN- gamma, granulocyte-macrophage-colony-stimulating factor, tumor necrosis factor-alpha, and histaminereleasing factors on the secretion of histamine from basophils. J Immunol. 1989;142:3431–5. [PubMed] [Google Scholar]
  • 44.Deare M, Bukholm G, Czarniecki CW. In vitro treatment of HEp-2 cells with human tumour necrosis factor alpha and human interferons reduces invasiveness of salmonella typhimurium. J Biol Regul Homeost Agents. 1989;3:1–7. [PubMed] [Google Scholar]
  • 45.Shemer-Avni Y, Wallach D, Sarov I. Reversion of the antichlamydial effect of tumour necrosis factor by tryptophan and antibodies to beta interferon. Infect Immun. 1989;57:3484–90. doi: 10.1128/iai.57.11.3484-3490.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Mestan J, Digel W, Mittnacht S, Hillen H, Blohm D, Moller A, Jacobsen H, Kirchner H. Antiviral effect of recombinant tumour necrosis factorin vitro. Nature. 1986;323:816–9. doi: 10.1038/323816a0. [DOI] [PubMed] [Google Scholar]
  • 47.Wong GHW, Goeddel DV. Tumour necrosis factors alpha and beta inhibit virus replication and synergise with interferons. Nature. 1986;323:819–22. doi: 10.1038/323819a0. [DOI] [PubMed] [Google Scholar]
  • 48.Ruggiero V, Antonelli G, Conciatori G, Gentile M, Van Damme J, Dianzani F. Thein vitro antiviral activity of tumor necrosis factor (TNF) in WISH cells is mediated by IFN-beta induction. Antiviral Res. 1989;11:77–88. doi: 10.1016/0166-3542(89)90010-7. [DOI] [PubMed] [Google Scholar]
  • 49.Janssen O, Kabelitz D. Tumour necrosis factor selectively inhibits activation of human B cells by Epstein-Barr virus. J Immunol. 1988;140:125–30. [PubMed] [Google Scholar]
  • 50.Koff WC, Farm AV. Human tumour necrosis factor alpha kills herpesvirus-infected, but not normal cells. Lymphokine Res. 1986;5:215–21. [PubMed] [Google Scholar]
  • 51.Matsuyama T, Hamamoto Y, Soma G, Mizuno D, Yamamoto N, Kobayashi N. Cytocidal effect of tumor necrosis factor on cells chronically infected with human immunodeficiency virus (HIV): enhancement of HIV replication. J Virol. 1989;63:2504–9. doi: 10.1128/jvi.63.6.2504-2509.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Kasahara K, Kobayashi K, Shikama Y, Yoneva I, Kaga S, Hashimoto M, Odagiri T, Soejima K, Ide H, Takahashi T. The role of monokines in granuloma formation in mice: the ability of interleukin-1 and tumour necrosis factor alpha to induce lung granulomas. Clin Immunol Immunopathol. 1989;51:419–25. doi: 10.1016/0090-1229(89)90040-8. [DOI] [PubMed] [Google Scholar]
  • 53.Sheppard BC, Fraker DL, Norton JA. Prevention and treatment of endotoxin and sepsis lethality with recombinant human tumor necrosis factor. Surgery. 1989;106:156–61. [PubMed] [Google Scholar]
  • 54.Brouckaert P, Spriggs DR, Demetri G, Kufe DW, Fiers W. Circulating Interleukin 6 during an infusion of tumour necrosis factor and interferon gamma. J exp Med. 1989;169:2257–62. doi: 10.1084/jem.169.6.2257. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Baumann H, Wong GW. Hepatocyte-stimulating factor III shares structural and functional identity with leukemia-inhibitory factor. J Immunol. 1989;143:1163–7. [PubMed] [Google Scholar]
  • 56.Waage A, Halstensen A, Espevik T. Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet. 1987;1:355–7. doi: 10.1016/s0140-6736(87)91728-4. [DOI] [PubMed] [Google Scholar]
  • 57.Millar AB, Foley NM, Singer M, Johnson NMCI, Meager A, Rook GAW. TNF in bronchopulmonary secretions of patients with adult respiratory distress syndrome. Lancet. 1989;ii:712–4. doi: 10.1016/s0140-6736(89)90772-1. [DOI] [PubMed] [Google Scholar]
  • 58.Kern P, Hemmer CJ, Van-Damme J, Gruss HJ, Dietrich M. Elevated tumor necrosis factor alpha and interleukin-6 serum levels as markers for complicated plasmodium facciparum malaria. Am J Med. 1989;87:139–43. doi: 10.1016/s0002-9343(89)80688-6. [DOI] [PubMed] [Google Scholar]
  • 59.Clark IA, Chaudhri G. Tumour necrosis factor may contribute to the anaemia of malaria by causing dyserythropoiesis and erythrophagocytosis. Br J Haematol. 1988;70:99–103. doi: 10.1111/j.1365-2141.1988.tb02440.x. [DOI] [PubMed] [Google Scholar]
  • 60.Clark IA, Chaudhri G. Tumor necrosis factor in malaria-induced abortion. Am J Trop Med Hyg. 1988;39:246–9. doi: 10.4269/ajtmh.1988.39.246. [DOI] [PubMed] [Google Scholar]
  • 61.Grau GE, Fajardo LF, Piguet PF, Allet B, Lambert PH, Vassalli P. Tumor necrosis factor (cachectin) as an essential mediator in murine cerebral malaria. Science. 1987;237:1210–2. doi: 10.1126/science.3306918. [DOI] [PubMed] [Google Scholar]
  • 62.Mintz M, Rapaport R, Oleske JM, Connor EM, Koenigsberger MR, Denny T, Epstein LG. Elevated serum levels of tumor necrosis factor are associated with progressive encephalopathy in children with acquired immunodeficiency syndrome. Am J Dis Child. 1989;143:771–4. doi: 10.1001/archpedi.1989.02150190021012. [DOI] [PubMed] [Google Scholar]
  • 63.Folks TM, Clouse KA, Justement J, Rabson A, Duh E, Kehrl JH, Fauci AS. Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc Natl Acad Sci USA. 1989;86:2365–8. doi: 10.1073/pnas.86.7.2365. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Okamoto T, Matsuyama T, Mori S, Hamamoto Y, Kobayashi N, Yamamoto N, Josephs SF, Wong-Staal F, Shimotohno K. Augmentation of human immunodeficiency virus type I gene expression by tumor necrosis factor alpha. AIDS Hum Retroviruses. 1989;5:131–8. doi: 10.1089/aid.1989.5.131. [DOI] [PubMed] [Google Scholar]
  • 65.Ito M, Baba M, Sato A, Hirabayashi K, Tanabe F, Shigeta S, De-Clercq E. Tumor necrosis factor enhances replication of human immunodeficiency virus (HIV)in vitro. Biochem Biophys Res Commun. 1989;158:307–12. doi: 10.1016/s0006-291x(89)80213-x. [DOI] [PubMed] [Google Scholar]
  • 66.Duh EJ, Maury WF, Folks TM, Fauci AS, Rabson AB. Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat. Proc Natl Acad Sci USA. 1989;86:5974–8. doi: 10.1073/pnas.86.15.5974. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Aboulafia D, Miles SA, Saks SR, Mitsuyasu RT. Intravenous recombinant tumor necrosis factor in the treatment of AIDS-related Kaposi's sarcoma. J Acquir Immune Defic Syndr. 1989;2:54–8. [PubMed] [Google Scholar]
  • 68.Tracey KJ, Wei H, Manogue KR, Fong Y, Hesse DG, Nguyen HT, Kuo GC, Beutler B, Cotran RS, Cerami A. Cachectin/tumor necrosis factor induces cachexia, anaemia, and inflammation. J Exp Med. 1988;167:1211–27. doi: 10.1084/jem.167.3.1211. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Waage A, Espevik T. Interleukin-I potentiates the lethal effect of tumour necrosis factor alpha/cachectin in mice. J Exp Med. 1988;167:1987–92. doi: 10.1084/jem.167.6.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Rothstein J, Schreiber H. Synergy between tumour necrosis factor and bacterial products causes haemorrhagic necrosis and lethal shock in normal mice. Proc Natl Acad Sci. 1988;85:607–11. doi: 10.1073/pnas.85.2.607. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Rook GAW, Taverne J, Leveton C, Steele J. The role of gamma-interferon, vitamin D3 metabolites and tumour necrosis factor in the pathogenesis of tuberculosis. Immunology. 1987;62:229–34. [PMC free article] [PubMed] [Google Scholar]
  • 72.Rook GAW. The role of cytokines in the immunopathology of tuberculosis and the regulation of agalactosyl IgG. Lymphokine Research. 1989;8:323–8. [PubMed] [Google Scholar]
  • 73.Pober JS. TNF as an activator of vascular endothelium. Ann Inst Pasteur Immunol. 1988;139:317–23. doi: 10.1016/0769-2625(88)90149-3. [DOI] [PubMed] [Google Scholar]
  • 74.Aderka D, Levo Y. Does tumor necrosis factor play a role in the pathogenesis of fulminant hepatitis. Med Hypotheses. 1988;27:193–6. doi: 10.1016/0306-9877(88)90140-5. [DOI] [PubMed] [Google Scholar]
  • 75.Wallach D, Holtmann H, Engelmann H, Nophar Y. Sensitisation and desensitisation to lethal effects of tumour necrosis factor and IL-1. J Immunol. 1988;140:2994–9. [PubMed] [Google Scholar]
  • 76.Kiener PA, Marek F, Rodgers G, Lin PF, Warr G, Desiderio J. Induction of tumour necrosis factor, IFN-gamma, and acute lethality in mice by toxic and non-toxic forms of lipid A. J Immunol. 1988;141:870–4. [PubMed] [Google Scholar]

Articles from Biotherapy (Dordrecht, Netherlands) are provided here courtesy of Nature Publishing Group

RESOURCES